Literature DB >> 415670

Examination of complement C3 metabolism in rheumatoid arthritis using 2-dimensional immunoelectrophoresis.

M F Shadforth, D C McNaughton.   

Abstract

A previous report that C3 activation products are demonstrable in the plasma of subjects with rheumatoid arthritis was reinvestigated using 2-dimensional immunoelectrophoresis. Initially it seemed that results were in agreement, but the occurrence of similar patterns in normal sera and poor reproducibility of results suggested the findings were artefacts. When calcium and magnesium ions were removed with EDTA, C3 activation products were no longer demonstrable in plasma from normal subjects or from patients with rheumatoid arthritis. The results obtained without EDTA in the buffer showed a greater degree of complement activation in patients with rheumatoid arthritis, suggesting that in this condition the serum may have a greater potential ability to bring about complement activation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 415670      PMCID: PMC1000182          DOI: 10.1136/ard.37.1.18

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  HEMOLYTIC COMPLEMENT IN SYNOVIAL FLUID.

Authors:  T J PEKIN; N J ZVAIFLER
Journal:  J Clin Invest       Date:  1964-07       Impact factor: 14.808

2.  STUDIES ON THE DEPRESSED HEMOLYTIC COMPLEMENT ACTIVITY OF SYNOVIAL FLUID IN ADULT RHEUMATOID ARTHRITIS.

Authors:  H HEDBERG
Journal:  Acta Rheumatol Scand       Date:  1963

3.  Complementary activity of the blood in rheumatism and certain allied disorders.

Authors:  C E KELLETT
Journal:  Ann Rheum Dis       Date:  1954-09       Impact factor: 19.103

4.  Anti-nuclear factors and serum complement in systemic lupus erythematosus.

Authors:  J H MORSE; H J MULLER-EBERHARD; H G KUNKEL
Journal:  Bull N Y Acad Med       Date:  1962-10

5.  The response of serum gamma globulin level and complement titer to adrenocorticotropic hormone therapy in lupus erythematosus disseminatus.

Authors:  J H VAUGHAN; T B BAYLES; C B FAVOUR
Journal:  J Lab Clin Med       Date:  1951-05

6.  Serum complement in rheumatoid arthritis.

Authors:  J H VAUGHAN; T B BAYLES; C B FAVOUR
Journal:  Am J Med Sci       Date:  1951-08       Impact factor: 2.378

7.  Electroimmuno assay.

Authors:  C B Laurell
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

8.  Hypocomplementemia in rheumatoid arthritis.

Authors:  A E Franco; P H Schur
Journal:  Arthritis Rheum       Date:  1971 Mar-Apr

9.  Complement metabolism in rheumatoid arthritis. I. Longitudinal studies.

Authors:  J M Versey; J R Hobbs; P J Holt
Journal:  Ann Rheum Dis       Date:  1973-11       Impact factor: 19.103

10.  Serum complement, rheumatoid factor, and other serum proteins in rheumatoid disease and systemic lupus erythematosus.

Authors:  H A ELLIS; D FELIX-DAVIES
Journal:  Ann Rheum Dis       Date:  1959-09       Impact factor: 19.103

View more
  2 in total

1.  Clinical applications of immunofixation: detection and quantitation of complement activation.

Authors:  J T Whicher; J Higginson; P G Riches; S Radford
Journal:  J Clin Pathol       Date:  1980-08       Impact factor: 3.411

2.  Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach.

Authors:  Sagarika Biswas; Saurabh Sharma; Ashish Saroha; D S Bhakuni; Rajesh Malhotra; Muzna Zahur; Michael Oellerich; Hasi R Das; Abdul R Asif
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.